GlassScriptPhysician profile
Daniel H Sarezky
NPI 1659716439
$3,349.90
in general payments reported to CMS, 2019-2025
27 companies · $754 in 2025
The $754 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $323 · 2021: $241 · 2022: $679 · 2023: $341 · 2024: $673 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $539.58 | 2022-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa, Photrexa Cross-Linking Kit |
| Alcon Vision LLC | $397.97 | 2019-2025 | Clareon, Eysuvis, Clareon Panoptix Pro |
| Rxsight INC | $320.24 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Mallinckrodt Hospital Products INC. | $310.68 | 2020-2025 | Acthar |
| New World Medical,INC. | $305.49 | 2022 | |
| Dompe US, INC. | $149.07 | 2019-2025 | Oxervate |
| Allergan, INC. | $140.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $129.58 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $125.52 | 2024-2025 | Xdemvy |
| Amgen INC. | $120.20 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $116.21 | 2019-2024 | Tecnis Simplicity |
| Abbvie INC. | $104.64 | 2022-2023 | Lumigan |
| Biotissue Holdings INC. | $97.15 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $95.15 | 2019 | |
| Avedro INC. | $89.42 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $80.94 | 2019-2021 | |
| Ocular Therapeutix, INC. | $32.60 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $29.82 | 2022 | |
| Bausch & Lomb Americas INC. | $24.66 | 2023 | Xiidra |
| Oyster Point Pharma, INC. | $23.13 | 2022 | |
| Genzyme Corporation | $21.41 | 2021 | |
| Aerie Pharmaceuticals, INC. | $20.27 | 2019 | |
| Sight Sciences, INC. | $16.92 | 2022 | |
| Ani Pharmaceuticals, INC. | $15.76 | 2024 | Purified Cortrophin Gel |
| Alcon Research LLC | $14.36 | 2019 | |
| Harrow Eye, LLC | $14.18 | 2025 | Triesence |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sarezky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.